Eva Fortea-Verdejo

VP, Equity Research – Biotechnology at Wells Fargo Corporate & Investment Banking

Speaker

Eva Fortea-Verdejo is a Vice President and Equity Research Analyst at Wells Fargo Securities, specializing in the biotechnology sector with coverage of companies such as iTeos Therapeutics, Arcus Biosciences, and Xencor. In her current role, she both supports a senior analyst and independently covers select biotech stocks, contributing to research publications and client advisory with a focus on interpreting clinical trial outcomes and stock impacts. She began her equity research career at Wells Fargo after earning her Ph.D. in 2021, with earlier roles spanning Cornell University, Concordia University, and the University of Valencia, and was promoted to vice president in 2024. Dr. Fortea-Verdejo holds advanced degrees in the biosciences and is professionally credentialed to conduct securities research and communicate investment recommendations to institutional clients.